Prahlad Singh, PhD
President and Chief Executive Officer
With more than 25 years of leadership experience working for global healthcare companies, Prahlad is professionally and personally motivated by the opportunity to make a positive impact on the world. Under his leadership, Revvity’s 11,000 employees deliver best-in-class solutions and service to a diverse range of organizations - advancing science that expands human health and improves lives worldwide.
Before his current role, Prahlad served as President and CEO of PerkinElmer, a position he was appointed to in 2019. During his time in this role, Prahlad led the company through a period of significant transformation - stewarding the organization through the COVID-19 pandemic and overseeing its dramatic portfolio evolution. He was also at the helm when the company completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, which resulted in the creation of Revvity. Prior to joining PerkinElmer in 2014, Prahlad was General Manager of GE Healthcare’s Women’s Health business. He has also held senior executive level roles in strategy, business development and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Born and raised in India, Prahlad holds a bachelor’s degree in chemistry from the University of Bombay. He moved to the United States to continue his academic career at the University of Missouri-Columbia, where he earned a PhD in chemistry. Prahlad also holds an MBA from Northeastern University’s D’Amore-McKim School of Business. Prahlad currently serves on the Board of Directors of Amphenol Corporation and the Analytical, Life Science & Diagnostics Association (ALDA). Additionally, he is a member of the Massachusetts General Hospital President's Council and an honoree of the Ascend Foundation’s 2023 A-List Awards recognizing outstanding Pan-Asian leaders.
Yves Dubaquie, PhD
Senior Vice President, Diagnostics
Yves Dubaquie is SVP of Diagnostics at Revvity, responsible for developing and executing the Company’s long-term strategy for its broad specialty diagnostics portfolio, which includes solutions that span immunodiagnostics, infectious disease testing, reproductive health and genomics.
Yves is an accomplished executive with over 20 years of broad healthcare industry experience. He is fascinated by technology and the process of deploying science to positively impact human health. Believing that diagnostics and therapeutics should work in concert to improve patient outcomes, Yves brings deep technical expertise and a collaborative mindset to his work. He encourages his team to leverage their unique skills, capabilities and experiences to work toward common goals and create value for the scientists, innovators and clinicians leveraging Revvity diagnostics solutions.
Prior to Revvity, Yves served three years as SVP of Diagnostics Solutions at MilliporeSigma, the Life Science business of Merck KGaA. Over the course of his career, he has also held various senior leadership and business development roles at Bristol-Myers Squibb, Novartis Molecular Diagnostics and GE Healthcare, among other companies.
Raised in Switzerland, Yves earned a PhD in biochemistry from the University of Basel and a master’s degree in natural sciences from ETH Zurich.
Alan Fletcher, PhD
Senior Vice President, Life Sciences
Dr. Alan Fletcher is the SVP of Life Sciences at Revvity. As both a scientist and a strategic business leader, Alan leads a team responsible for shaping the company’s Life Sciences portfolio and delivering solutions that accelerate breakthrough discoveries across therapeutic areas.
Believing that a unified vision and strategy can help solve the world’s greatest health challenges, Alan is a driven and supportive leader who has been instrumental in realizing the company’s R&D vision – transforming innovation from target to cure. Under his leadership, the Life Sciences business has launched numerous market-leading and first-in-class products for existing and emerging areas of science and disease. Alan is a proponent of democratizing technologies for the advancement of new and novel treatments, such as cell and gene therapies, and leads an initiative at Revvity that provides incubator labs and biotech startups with state-of-the-art equipment and resources to fuel their innovation.
Since joining the company in 2008, Alan has held a variety of progressive leadership positions within the Life Sciences business. During this time, he spent one year living and working in China as VP and GM of Sales & Service for the Asia-Pacific region – an opportunity and period of time in his career that he remembers fondly. With more than 30 years of overall experience in the life sciences industry, Alan has also held leadership positions at GE Healthcare Life Sciences as well as Merck & Co. in the United Kingdom.
Born and raised in Wales, Alan earned his PhD in biochemical pharmacology from the University of London, and a bachelor’s degree in biochemistry from Surrey University in the UK. He has been published in more than 30 peer-reviewed publications and served seven years in leadership positions of the Society for Laboratory Automation and Screening (SLAS) and its predecessor the Society of BioMolecular Sciences (SBS).
Senior Vice President, Chief People and Culture Officer
Magali Four is SVP and Chief People and Culture Officer of Revvity. She is responsible for setting the company’s strategic HR agenda and works in close partnership with company leaders to foster an inclusive culture that empowers 11,000 employees to thrive.
Magali is an action-oriented and empathetic leader who champions the company’s values – particularly a passion for people. Believing that engaged employees who are cared for as human beings are an organization’s greatest strength, she is committed to developing and nurturing talent within Revvity as well as continuously enriching company culture. Magali leads an ambitious and purpose-driven team of HR professionals that spans 15+ countries to support Revvity employees worldwide. She plays a leading role in their efforts to build high-performing teams, attract top talent and create positive experiences for employees across the organization.
Before being appointed to her current role in February 2021, Magali served in various HR leadership roles at companies including Intel, GE Healthcare in the Women’s Health segment and at GE Real Estate.
Magali is a graduate of the NEOMA Business School in France. She also holds a European HR Management Certificate from the Institut de Gestion Sociale in Paris.
Senior Vice President, Administration, General Counsel and Secretary
Joel Goldberg is SVP, Administration, General Counsel and Secretary of Revvity – a role in which he applies expert insights and strategic thinking to a variety of legal, regulatory and policy issues affecting the Company.
As a core member of Revvity’s senior leadership team, Joel leads dedicated and solutions-driven teams that work collaboratively and across the business to provide support and guidance on a range of matters and other corporate issues. By encouraging creative thinking and problem-solving, Joel strives to foster an open and honest culture that enables Revvity employees to do their best work on behalf of the business and the organizations it serves.
Prior to joining the Company in July 2008, Joel spent seven years at Millennium Pharmaceuticals, Inc., where he most recently served as VP, Chief Compliance Officer and Secretary. During his time in that role, Joel focused in the areas of mergers and acquisitions, securities and healthcare related compliance and employment law. Before that, Joel was an associate of the law firm Edwards & Angell, LLP (now part of Locke Lord LLP).
Joel is a Boston native and graduate of the Northeastern University School of Law. He completed his undergraduate studies at the University of Wisconsin-Madison and also holds an MBA from Northeastern University.
Madhuri Hegde, PhD
Senior Vice President and Chief Scientific Officer
Dr. Madhuri Hegde, FACMG, is the SVP and Chief Scientific Officer of Revvity, responsible for setting the strategic scientific direction of the Company. As both a medical geneticist and American Board of Medical Genetics and Genomics (ABMGG) certified diplomat in clinical molecular genetics, Madhuri is also the head of Revvity Omics and its global network of laboratories offering innovative, omics-based services in more than 155 countries worldwide.
Madhuri is a passionate and perpetually curious leader whose team is committed to delivering cutting-edge products to Revvity customers, while keeping a close eye on innovation and bringing those developments to market. Madhuri is energized by bringing people and teams together to make a difference and harness science to positively impact human health.
Making the switch from academia to industry in 2016, Madhuri joined Revvity from Emory University in Atlanta, where she served as Executive Director of the Emory Genetics Laboratory and as a professor of human genetics and pediatrics. Before that, she spent several years at the Baylor College of Medicine where she was faculty in the Department of Human Genetics and Director at Baylor Medical Laboratories. She also served several years as a laboratory director at Auckland City Hospital in New Zealand.
Madhuri currently serves on the board and is an officer of the American College of Medical Genetics and Genomics Foundation (ACMGF), and leads the ACMG’s International Outreach and Engagement Committee. She is also a member of the ABMGG Board of Directors, serves on Coriell Cell Repositories NIGMS Human Genetic Cell Repository Scientific Advisory Committee, co-chairs ClinGen’s PTEN committee and is a member of the NHGRI ClinGen Hereditary Cancer Executive Committee. She is an adjunct professor of Pediatrics at Emory University School of Medicine and at Georgia Institute of Technology; has either authored or co-authored over 150 peer-reviewed publications and eight book chapters; and presented well over 100 keynote and other invited presentations at major national and international conferences.
Exposed to science and the field of genetics at an early age, Madhuri’s decision to pursue a career in this field was heavily influenced by academics and other scientists in her family. She was born and raised in India and earned her bachelor’s and master’s degrees in microbiology at the University of Mumbai. Madhuri also holds a PhD in applied biology and genetics from the University of Auckland, and completed her postdoctoral studies and ABMGG certification at Baylor College of Medicine.
Senior Vice President and Chief Financial Officer
Max Krakowiak is SVP and Chief Financial Officer at Revvity, responsible for leading the Company’s global finance organization.
Max is a team player who fosters a strong culture centered on camaraderie, talent development and winning the controllables. He has played an integral role on Revvity’s finance leadership team since 2018. Before being appointed to his current role in August 2022, Max served as VP of Corporate Finance overseeing financial planning and analysis as well as the commercial and business development finance organizations. He has also served as the Company’s chief of staff for finance and focused on driving global finance transformation through people, process and automation.
Prior to joining the Company, Max spent seven years at GE where he most recently served as a member of the executive leadership team in the company’s corporate audit staff. He worked across GE’s global operating segments to oversee teams responsible for corporate strategy, external investigations and investor relations. Max is also a graduate of the GE Financial Management leadership program.
Max holds a bachelor’s degree in finance from Fordham University in New York City. He also spent time as a minor league baseball player in the Seattle Mariners organization.
Yi-Ping Lin, PhD
Senior Vice President, Chief Quality, Regulatory and Clinical Officer
Dr. Yi-Ping Lin is SVP, Chief Quality, Regulatory and Clinical Officer at Revvity. She brings more than 25 years’ experience in the IVD industry to this role and leads the Company’s QRC team in efforts that accelerate business success.
Yi-Ping is an energic and enthusiastic leader who strives to foster a creative, compliant culture. Her wide-ranging experience in research and development, product support, operations and manufacturing are foundational in her day-to-day work leading Revvity’s QRC team. While remaining laser-focused on building QRC excellence to fuel competitive advantage, Yi-Ping encourages her team to think outside-the-box in how to partner with the business in developing and delivering quality human health solutions to market. Yi-Ping is passionate about diversity and inclusion in the workplace and champions efforts that support and advocate for women and people of color in leadership positions.
Before joining Revvtiy, Yi-Ping worked at Cepheid (a Danaher Corporation company) as SVP, Quality Regulatory and Clinical Affairs, where she led a global QRC organization of more than 700 employees. She has also worked in various leadership roles at Beckman Coulter, Abbott, Roche and Johnson & Johnson (J&J). During her tenure at J&J, Yi-Ping was honored with the New Jersey Tribute to Women and Industry (TWIN) Award in recognition of her significant contributions to the organization and achievements in her field.
Yi-Ping earned a PhD in biochemistry from Rutgers University, where she also completed post-graduate work at the Robert Wood Johnson Medical School.
Senior Vice President, Strategy and Business Development
Dan Tereau is SVP of Strategy and Business Development at Revvity – a position he was appointed to in January 2016. He leads a team of collaborative and keenly intelligent strategists who drive global business development initiatives and are united in the Company’s purpose expand the boundaries of human potential through science.
With more than 30 years’ experience in corporate business development and strategic planning, Dan brings a multifaceted skill set to his work at Revvity. He is energized by the opportunity to do something new every day and believes that learning and growing are the essence of life. To Dan, fearless ambition means tackling challenges without knowing what the outcome may be – whether it’s expanding access to prenatal testing in underserved areas or working through the discovery process to bring a new drug to market.
Before joining the company in 2014, Dan served on Novartis’ leadership team as SVP and Global Head of Strategy, Business Development and Licensing for its consumer health division. Over the course of his career, he has held similar roles at GE Healthcare and Thermo Fisher Scientific.
Dan earned a bachelor’s degree in finance from Ferris State University, a JD from Wayne State University and an MBA from Yale University.
Senior Vice President, Global Chief Information Officer
Jayashree Thacker is SVP and Global Chief Information Officer at Revvity overseeing information technology and digital transformation. The impact of her team’s work provides the Company with solutions and services that deliver the agility needed for superior customer experience, sustainable business growth and optimal return on investment, in a compliant environment.
With more than 35 years of broad business and consulting experience, Jayashree is a technically savvy and skilled leader. She leads by example with a fierce dedication to her work, believing that this evokes a similar commitment from her team of more than 180 IT professionals worldwide. Jayashree’s team has led the modernization of Revvity’s infrastructure, security and applications, including ongoing e-commerce transformation. By remaining constantly curious about emerging technologies, Jayashree is continuously looking for new opportunities to transform the organization using technology.
Before being appointed to her current role in February 2020, Jayashree served as the company’s President for India South Asia & Emerging Markets, where she developed and directed strategies to grow the business across multiple geographies. She also spearheaded the build of Revvity’s multi-functional Global Delivery Centre in India. Before that, Jayashree spent more than 12 years in various leadership roles in the life sciences and healthcare verticals of IBM. She has also held various business consulting positions at PricewaterhouseCoopers and Coopers & Lybrand.
Jayashree completed her undergraduate studies in pharmaceutical sciences at the Institute of Chemical Technology (ICT), Mumbai, and in 2017 received its UAA-ICT Distinguished Alumnus Award in the Professionals category. She also completed an MBA at the Indian Institute of Management, Ahmedabad, and an executive development and leadership program at Cornell University’s Samuel Curtis Johnson Graduate School of Management. Jayashree has also served in various faculty roles at some of the largest business schools in Mumbai.
Senior Vice President and Chief Commercial Officer
Miriame Victor is SVP and Chief Commercial Officer at Revvity. She leads a global team responsible for bringing innovative products and solutions to market that solve problems and expand the boundaries of human potential for Revvity’s customers, partners and collaborators across health and science.
Miriame believes that the future of better human health will involve accessible and easy-to-use diagnostics as well as breakthrough solutions across disease pathways. To realize this vision, she and her team work cross-functionally with Revvity business leaders, product management, R&D professionals and others to deliver complete workflows from discovery to development, and diagnosis to cure. She brings more than 20 years’ experience working in the pharmaceutical, medical device and diagnostics industries to this role and is inspired by embracing the impossible to improve lives everywhere.
Since joining the company in 2014, Miriame has held a number of progressive leadership positions – most recently serving as VP and General Manager of the EMEAI region. She has also worked in various commercial leadership roles at GE Healthcare, Novartis and Merck. She is a graduate of the Experienced Commercial Leadership Program at GE and a certified Six Sigma Black Belt.
Born and raised in Egypt, Miriame earned her bachelor’s degree in clinical pharmacy from Cairo University. She also earned an MBA with a concentration in strategic management from the Arab Academy for Science, Technology and Maritime Transport.
Senior Vice President, Global Operations
Tajinder Vohra is SVP of Global Operations at Revvity, responsible for overseeing the Company’s manufacturing, supply chain, customer care and distribution functions.
Appointed to his current role in 2015, Tajinder brings nearly 30 years’ experience in operations management to the Revvity team. Originally attracted to this field for its sense of action and urgency, Tajinder leads a global team that collaborates deeply with R&D and Product Management to launch and manufacture products across the Company’s Life Sciences and Diagnostics businesses. His team has reengineered complex fulfillment networks and created digital backbones for eCommerce. He has led technology transfers across multiple countries while managing regulated products and geographically distributed teams.
Prior to his current role, Tajinder ran Operations for ABB in India and its regional supply chain in the Middle East, Africa and India. Before ABB, Tajinder was working in Genpact, a spinoff of GE and a Bain capital company. He helped broaden the service portfolio of the company by incubating and scaling supply chain practices before a successful IPO on the NYSE. Earlier in his career Tajinder worked at GE Healthcare across multiple functions.
Tajinder earned his bachelor’s degree in mechanical engineering from the University of Delhi, a master’s degree in industrial engineering from the University of Alabama and a master’s degree in manufacturing engineering from Lehigh University.
Senior Vice President and General Manager, Revvity Signals Software
Kevin Willoe is SVP and General Manager of Revvity’s Signals Software, which offers a comprehensive suite of enterprise software solutions that enable life-changing breakthroughs across health and science.
Kevin is an entrepreneurial enterprise software executive with more than 25 years’ experience in the IT industry. Under his leadership, the Revvity Signals Software team has a proven track record of meeting or exceeding revenue targets and key business objectives, while enabling customer success in solving critical healthcare issues. Working at the leading edge of today’s continuously evolving technology market, Kevin and his team of more than 800 dynamic, dedicated software professionals are committed to delivering innovative solutions that empower scientists and accelerate research and development.
Before being appointed to his current role, Kevin spent several years in other leadership positions within the company’s Signals business unit, including VP and General Manager and VP of Global Sales. Over the course of his career, Kevin has also worked for Zephyr Health, Spotfire Software (acquired by TIBCO) and MKS Software (acquired by PTC).
Kevin is a graduate of Northeastern University where he earned a bachelor’s degree in business administration.
Vice President, Digital & Technology
Arvind Sundar-Rajan is VP of Digital and Technology at Revvity, responsible for advancing common capabilities and technology platforms across the Company – from science to the cloud, and from sample to answer. In addition to oversight of the Technology teams at Revvity tasked with bringing new products and services to market, Arvind plays a leading role in driving the Company’s digital transformation strategy and execution.
Prior to being appointed to his current role, Arvind led the divestiture of the Company’s Applied, Food and Enterprise Services businesses to New Mountain Capital, which resulted in the creation of Revvity. Leveraging his strategic mindset and collaborative spirit throughout this complex endeavor, Arvind has helped drive meaningful value for the business over the course of its portfolio transformation, helping ensure Revvity makes an impact across its various end markets. Having initially joining the Company in 2017 as Strategy and M&A Leader, Arvind has also served as VP and General Manager of Revvity’s ViaCord business, a leader in private cord blood and cord tissue banking.
As a strong believer in the impact leadership and culture can have in building high performance teams, Arvind strives to cultivate a mission-based environment in which all members of his team can thrive. He champions Revvity’s purpose to expand the boundaries of human potential through science and is committed to continuous learning and improvement – particularly in understanding how to apply emerging technologies like artificial intelligence and machine learning to the world’s greatest health challenges.
Prior to joining Revvity, Arvind spent more than 15 years at GE Healthcare where he worked in various progressive leadership roles in digital technology, strategy, mergers and acquisitions and business transformation. He is also a graduate of GE’s Information Technology Leadership Program.
Arvind is a graduate of Drexel University in Philadelphia, Pennsylvania, where he earned a bachelor’s degree in information science and technology. He also holds an MBA from the University of Chicago Booth School of Business.
Board of Directors
- Alexis P. Michas
Managing Partner, Juniper Investment Company, LLC - Non-Executive Chairman
Mr. Michas is the founder and has been Managing Partner of Juniper Investment Company, LLC since 2008. Juniper is also a Principal of Aetolian Investors, LLC, a registered commodity pool operator. Mr. Michas received a Bachelor of Arts degree from Harvard College and a Master of Business Administration degree from Harvard Business School. Mr. Michas is the Non-Executive Chairman of the board of BorgWarner Inc., a director of funds managed by Atlantic Investment Management, Inc., a board member of publicly traded AstroNova, Inc., as well as privately held Theragenics Corporation. Mr. Michas also served as the Non-Executive Chairman of the board of Lincoln Educational Services Corporation until 2015, and as a director of Allied Motion Technologies, Inc. until July 2017. Mr. Michas is the Chairman of the U.S. Board of Trustees of Athens College, a non-profit organization.
Mr. Michas was named Non-Executive Chairman of the board as of December 30, 2019. He brings to our board, and to the position of Non-Executive Chairman, many years of private equity experience across a wide range of industries, and a successful record of managing investments in public companies. Mr. Michas also brings extensive transactional expertise, including mergers and acquisitions, IPOs, debt and equity offerings, and bank financing. This expertise allows Mr. Michas to provide our board with valuable insight on trends in global debt and equity markets, and the impact of such trends on the capital structure of the Company. We also benefit from the corporate governance knowledge developed by Mr. Michas in his board roles with other public companies, including his service as a board chairman, a lead director, and a member of the compensation, governance, audit, finance and executive committees of such companies. Mr. Michas’ thorough knowledge of the Company and his current and past service on the boards of other public companies make him uniquely qualified to serve as our Non-Executive Chairman.
- Peter Barrett
Partner, Atlas Venture
Mr. Barrett joined Atlas Venture, an early stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Prior to that, Mr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. He currently serves as the Chairman of Synlogic, Inc., and as a board member of Larimar Therapeutics and several privately held companies. Mr. Barrett is also a senior fellow at the Harvard Business School.
Mr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Doctoral degree in analytical chemistry from Northeastern University.
Mr. Barrett brings to the board more than three decades of experience in the life sciences industry, including leadership positions both as a senior executive and as an institutional investor. These roles have allowed him to develop expertise in the deployment of strategic growth initiatives within the industry. His service as chair and as a member of the boards of other companies, both publicly and privately held, enables him to assist our board in the performance of its governance obligations.
- Samuel R. Chapin
Retired Executive Vice Chairman, Bank of America Merrill Lynch
Mr. Chapin was appointed Executive Vice Chairman of Global Corporate & Investment Banking at Bank of America Merrill Lynch in February 2010, where he was responsible for managing relationships with some of the firm's largest clients. Mr. Chapin retired from the firm as of June 30, 2016.
Mr. Chapin was named Vice Chairman of Merrill Lynch & Co in September 2003 and was a member of the firm's executive Operating Committee. From 2001 to 2003, he was Senior Vice President and Head of the Global Investment Banking division. Prior to that, he led the group within investment banking that covered industrial companies. He actively managed the firm's relationships with clients primarily in the industrial, resources and consumer products industries. Mr. Chapin has worked on a broad range of financings and strategic advisory assignments totaling more than $500 billion. Investment Dealers' Digest also named him Investment Banker of the Year.
Mr. Chapin joined Merrill Lynch in 1984 as a member of the Mergers & Acquisitions group and was named a managing director in Corporate Banking in 1993. He previously worked for Chase Manhattan Bank for three years in the corporate banking group. He is also a member of the board of directors of the Roundabout Theatre Company. He also serves on the board of trustees at Lafayette College and is a director for the Wharton Financial Advisory Board. Mr. Chapin is a member of the board of directors of CICOR International, Inc., a leading provider of flow control solutions and other highly engineered products for the industrial, energy and aerospace markets, O-I Glass, Inc., a world leader in glass bottle manufacturing, and PHINIA, a leader in the automotive components industry, all three of which are publicly-traded. Mr. Chapin was appointed a Senior Advisor to Rockefeller Capital Management, a leading independent, privately-owned financial services firm, in May 2019.
Mr. Chapin received a Bachelor of Arts from Lafayette College, where he was elected to the Phi Beta Kappa honor society. He also received a Master of Business Administration, with distinction, from The Wharton School at the University of Pennsylvania. Mr. Chapin brings to our board extensive knowledge of the industrial marketplace, along with deep experience in strategic advisory, mergers and acquisitions, and deal financing for a wide range of transactions.
- Dr. Sylvie Grégoire, PharmD
Advisor to biotechnology companies
Dr. Grégoire served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013 and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Grégoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. (now known as Biogen Idec Inc.) and Merck & Co.
Dr. Grégoire currently serves on the board of Novo Nordisk and CervoMed. Dr. Grégoire holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.
Dr. Grégoire provides the board with a depth of experience in the management of commercial operations, manufacturing and regulatory affairs within the biotechnology industry, both domestically and internationally. Her extensive background gained over the course of almost thirty years of leadership positions with both public and private companies, as well as her current and past service on the boards of other public companies, will provide the board with valuable guidance in overseeing the strategic direction of the Company.
- Dr. Michelle McMurry-Heath
Consultant to Biotechnology Industry
A medical doctor and molecular immunologist by training, Dr. Michelle McMurry-Heath most recently served as President and Chief Executive Officer of the Biotechnology Innovation Organization (BIO). She came to BIO from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences.
Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation’s policies, programs and personnel. President Obama then named her associate science director of the FDA’s Center for Devices and Radiological Health.
Dr. McMurry-Heath was the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation.
Dr. McMurry-Heath also serves on the Board of Directors at Bioventus. She received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program. She spent 12 years working at the research bench before taking policy and leadership roles in government and industry.
- Prahlad Singh, PhD
President and Chief Executive Officer, Revvity
Dr. Singh was elected President and Chief Executive Officer of Revvity effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined Revvity as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining Revvity, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region.
Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. He also currently serves on the Board of Directors of Amphenol Corporation and the Analytical, Life Science & Diagnostics Association (ALDA). Additionally, he is a member of the Massachusetts General Hospital President's Council. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent eight years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.
- Michel Vounatsos
Former Chief Executive Officer of Biogen Inc.
Mr. Vounatsos is the former Chief Executive Officer of Biogen Inc., a publicly-traded company based in Cambridge, Massachusetts, having served in that position and been a member of Biogen’s board of directors from 2017 to 2022. Prior to joining Biogen in April 2016 as Executive Vice President, Chief Commercial Officer, Mr. Vounatsos spent twenty years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, Mr. Vounatsos led Merck’s global primary care business unit, encompassing Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves on the board of directors of Zai Lab limited, the advisory board of Tsinghua University School of Pharmaceutical Sciences, the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, the board of directors of N-Lorem Foundation and as a member of the MIT Presidential CEO Advisory Board. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.
Mr. Vounatsos joins our board with significant knowledge and broad-based experience with respect to the biotechnology, healthcare and pharmaceutical industries, a comprehensive global leadership background resulting from service as an executive in the pharmaceutical industry and his educational background in medicine and business. Mr. Vounatsos also brings valuable leadership skills gained as the chief executive officer of a publicly-traded multinational organization.
- Frank Witney
Former Chief Executive Officer, Affymetrix, Inc.
Dr. Witney most recently served as President and Chief Executive Officer of Affymetrix, Inc. (now part of Thermo Fisher Scientific), which specialized in microarray technology and cellular analysis. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix when it acquired Panomics Inc., a quantitative biology company, which he led as President and Chief Executive Officer. He previously held the role of President of PerkinElmer’s Drug Discovery Tools division following the acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market.
Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation, Codex DNA and Standard BioTools, as well as several privately held companies, and is an Operating Partner at Ampersand Capital Partners.
Dr. Witney brings deep market knowledge and over 30 years of leadership experience across the life sciences, diagnostics and analytical instruments industry.
- Pascale Witz
Former Executive Vice President, Diabetes and Cardiovascular, Sanofi, S.A.
Ms. Witz brings more than two decades of global healthcare management experience to the Board. She most recently served as executive vice president, global diabetes and cardiovascular at Sanofi. During her tenure with the company, she launched multiple medicines across three continents and strengthened the pipeline through licensing and partnerships.
Prior to joining Sanofi, Ms. Witz served more than 17 years at GE Healthcare which included her final role as president and chief executive officer of its medical diagnostics business, a $2 billion integrated pharmaceutical organization that encompassed research and development through commercial.
Ms. Witz received her Master of Business Administration in Economics and Marketing from INSEAD and her Master of Science in Biochemistry from INSA Lyon. She currently serves on the board of directors for Horizon Pharma Plc, Regulus Therapeutics, Inc., and Fresenius Medical Care AG & Co. KGaA.